- Market Capitalization, $K 199,111,584
- Shares Outstanding, K 2,291,800
- Annual Sales, $ 53,166 M
- Annual Income, $ 12,611 M
- 60-Month Beta 0.59
- Price/Sales 3.85
- Price/Cash Flow 10.71
- Price/Book 3.88
|Period||Period Low||Period High||Performance|
| || |
+0.60 (+0.70%)since 09/18/19
| || |
-7.38 (-7.83%)since 07/18/19
| || |
+11.02 (+14.53%)since 10/18/18
Companies in the analgesics market are increasingly focusing on acquisition as a strategy for growth. Leading analgesic drug manufacturers are acquiring smaller companies to gain competitive advantage...
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.
Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.
Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include GlaxoSmithKline...
Eyevance Pharmaceuticals, committed to developing and commercializing innovative and impactful ophthalmic products, is pleased to announce the acquisition of TOBRADEX® ST (tobramycin/dexamethasone ophthalmic...
Ocular drug delivery refers to the treatment of ophthalmic diseases. Ophthalmic diseases affect various parts of the eye anatomy, are specified on the basis of their position namely, anterior segment and...
Numab Therapeutics AG today announced that effective October 1 it has appointed former Novartis CEO and Chairman Dr. Daniel Vasella to its Board of Directors.
Market Study Report, LLC's latest research report on 'Specialty Generic Drugs Market' delivers a comprehensive study on current market trends. The outcome also includes revenue forecasts, statistics, market...
The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
|Long/Short Equity ETF FT|
|Pharmaceutical Vaneck ETF|
|Bldrs Developed Markets 100 ADR Index Fund Inves|
|Bldrs Europe Select ADR Index Fund Invesco|
|Intl Dividend Achievers Invesco ETF|